Atai Life Sciences
Tracked across 3 events · 61 articles · First seen Apr 18, 2026 · Last active Jul 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Atai Life Sciences received a Silver Award in Ovid Health's 2026 Patient Participant Index for its collaboration with Psychedelic Participant Advocacy Network, enhancing its reputation in patient-informed research and potentially boosting investor confidence.
Apr 27, 2026 · 7 articles
Business
Impact: Atai Life Sciences is the target, receiving a 26% premium on its stock price. The acquisition provides access to Lilly's resources to accelerate development of its psychedelic therapies, particularly BPL-003 for treatment-resistant depression.
Jul 16, 2026 · 25 articles
Regulatory
Impact: Atai Life Sciences is a company studying MDMA and other psychedelic compounds, benefiting from investments from figures like Peter Thiel as the regulatory environment shifts.
Apr 18, 2026 · 29 articles
ERGEN INTELLIGENCE
Track Atai Life Sciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard